Navigation Links
Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
Date:3/12/2008

ded December 31, 2007, the Company reported a net loss of $23.3 million, or $0.79 per share, compared with a net loss of $56.8 million, or $2.52 per share, for the year ended December 31, 2006. (All share and per-share data have been retroactively adjusted to account for the effect of a 1-for-6 reverse stock split on July 13, 2007.)

Net product sales of $0.3 million for the fourth quarter of 2007 increased from $0.1 million for the fourth quarter of 2006, primarily due to a reduction in a provision for sales returns of Ganite(R) of $0.1 million. Net product sales for the year ended December 31, 2007 of $0.6 million declined from the prior-year period of $0.7 million as product sales in 2007 and 2006 included favorable adjustments to a reserve for returns of Ganite of $0.1 million and $0.3 million, respectively. Operating expenses for the fourth quarter and the year ended December 31, 2007 declined from their comparable prior-year periods, as the prior year included a buildup of sales, marketing and manufacturing expenses incurred in preparation for a possible commercial launch of Genasense. In addition, lower expenses in 2007 reflect the impact of a staff reduction in December 2006.

In the fourth quarter of 2006, the Company recorded an expense of $5.3 million that provided for the issuance of 2 million shares of Genta common stock, for a settlement in principle of class action litigation. The expense is net of insurance recovery of $18.0 million. At December 31, 2007, the revised estimated value of the common shares portion of the litigation settlement is $1.0 million based on a closing price of Genta's common stock of $0.52 per share, resulting in a reduction in the provision of $1.6 million and $4.2 million for the fourth quarter and year ended December 31, 2007, respectively.

Also in the fourth quarter of 2006, we accounted for the impairment of prepaid royalties and recorded a write-off of this asset of $1.3 million due to the non-approvabl
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
2. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
4. Genta Clinical Programs Featured at American Society of Hematology Meeting
5. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
6. Genta Incorporated Announces Third Quarter 2007 Financial Results
7. Genta Initiates First Clinical Trial with New Oral Drug (G4544) to Treat Bone Disease
8. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
9. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
10. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
11. Inclinix Announces New Patent for Expert System Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...HAPEL HILL, N.C., Nov. 25 Cempra P...hi Fernandes, president and chief executive office...ealth Care Conference at 8:50 a.m. EST, December 1...ity. Dr. Fernandes will provide an overview of th...ms for the treatment of drug-resistant pathogens i...
(Date:11/25/2009)... NEW YORK, Nov. 25 Reportlinker.co...vailable in its catalogue: ,, Intranasal Drug ...//www.reportlinker.com/p0164267/Intranasal-Drug-De...e US intranasal drug delivery market is witnessing... delivery of conventional local therapeutic drugs ...
(Date:11/25/2009)...MINGHAM, Mass. and SYDNEY, Nov. 25 /PRNewswire-Fir... HTWR ; ASX: HIN), a leading innovator and provide...rt technologies revolutionizing the treatment of a...scheduled to make an investor presentation at the ...t 8:00 am EST on Wednesday, December 2, 2009. The ...
Breaking Medicine Technology:Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 2Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 3Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 4Reportlinker Adds Intranasal Drug Delivery - US Market Trends & Analysis 5HeartWare to Present at 21st Annual Piper Jaffray Health Care Conference in New York City 2Springer Series editor John Smol receives two prestigious biology awards 8696 1Springer Series editor John Smol receives two prestigious biology awards 8696 2Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine 8693 1Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine 8693 2Enzyme involved in inflammatory bowel disease discovered at Penn State College of Medicine 8693 3LCA Vision Reports on Annual Meeting of Stockholders 47638 1LCA Vision Reports on Annual Meeting of Stockholders 47638 2LCA Vision Reports on Annual Meeting of Stockholders 47638 3LCA Vision Reports on Annual Meeting of Stockholders 47638 4
...earchers led by Bruce Boman, M.D., Ph.D. director ...len F. Graham Cancer Center of the Christiana Care...rsity of Delaware , have discovered an enzyme comm...hat will assist scientists searching for a cure fo...om/cgi-bin/prnh/20090407/DC95299LOGO ) , , To da...
...of PlasmaBlade by U.S. Surgeons Since Product Laun...l, Inc., a medical device company that has develop...ietary technology, announced today several milesto...ncludes the PULSAR(R) Generator and the PEAK Plasm...urgical cutting and coagulation devices. These mil...
Other Medicine Technology:Discovery of Marker for Colon Stem Cells Could Shed Light on What Drives Tumor Growth 2PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 2PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 3PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM) 4
(Date:11/27/2009)...ycling plus low-emission vehicles may reduce futur...IDAY, Nov. 27 (HealthDay News) -- Encouraging city...s would offer much greater public health benefits ... researchers have found. , The study compared t... urban land transport scenarios for London, Englan...
(Date:11/27/2009)... Multi-purpose bilingual coloring book... use by the business community to educate - inform...ts from Safety issues to Dinosuars to ABC,S and a ...aint Louis, MO (PRWEB) November 27, 2009 -- Today&...or toys to keep them busy any hour of the day, but...
(Date:11/26/2009)... PRINCETON, N.J., Nov. 27 The diab...ouble over the next 25 years and annual medical sp...lion, up from $113 billion today, according to a s...Care . The National Changing Diabetes ® Pro...ed the analysis by a team from the University of C...
(Date:11/26/2009)...gger thrill when on an emotional rollercoaster, st...ay News) -- Call it the fear factor meets the jubi...ectators -- especially those who root for the winn...s a closely contested match and victory was in dou..., Chew on that this Thanksgiving weekend as you...
(Date:11/26/2009)... Benton Communications announces a hig...ystem for retailers struggling to make an economic...mber 26, 2009 -- Flu fears is the type of challeng...gency room, according to Dr. David Benton, busines...usiness growth system – The Rfactor Intensi...
Breaking Medicine News(10 mins):Health News:More Foot Power, Less Car Pollution Best for Health 2Health News:Really Big Coloring Books Debuts Bi-Lingual Spanish-English Line of Custom and Imprintable Coloring Books 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 2Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 3Health News:Diabetes Population to Double, Diabetes Costs to Nearly Triple, in 25 Years, New Study Shows 4Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Pharmacist Injects Cure for Ailing Businesses 2
...Health Care announced today that its newest member...egaderm™ CHG (chlorhexidine gluconate) IV Se...m, surface antimicrobial activity against diverse ...ual Scientific Meeting of the Society for Healthca...
...Webster Executives Join Stereotaxis, ST. LOUIS, A...announced today that it has made two strategic add...appointed Kevin Shifrin, most,recently the Vice Pr... Development. The Company has also appointed,Magnu...
...s, a leading provider of,Business Process Outsourc...hat it has hired Jan Claesson as Senior Vice Presi...son was selected for his extensive leadership,back...bin/prnh/20050113/SFTH042LOGO ), Adaptis Chief Ex...
...08 Varian, Inc.,(NasdaqGS: VARI) announced today ...ivately owned company based in Abingdon, U.K. Oxfo...y, an analytical technique used by,scientists in p...crystalline compounds, x-ray crystallography is th...
... News stories about an allegedly harmful link betw... onset of autism had little effect on whether U.S....review of immunization records and news stories. P...s Hospital of Philadelphia and The University of L...
... women found that the brains of one-third of indiv...ce of small, cumulative blood vessel damage that c...mas Montine and colleagues analyzed the brain tiss...neurological and psychological tests every two yea...
Other Medicine News:Health News:New data on 3M's Tegaderm CHG 2Health News:Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe 2Health News:Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe 3Health News:Stereotaxis Appoints Senior Vice President of Global Marketing and General Manager for Europe 4Health News:Adaptis Names Jan Claesson Senior Vice President and Chief Business Development Officer 2Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 2Health News:Varian, Inc. Acquires Oxford Diffraction, Ltd. 3Health News:Parents follow pediatrician advice on administering MMR vaccinations 2Health News:Parents follow pediatrician advice on administering MMR vaccinations 3
Jameson Muscle Forceps - Child Size - Left
Trouan Superior Rectus Forceps
MacGregor Conjunctival Forceps
Akahoshi Prechop Forceps - Curved
Medicine Products: